TNF Polymorphisms and Bladder Cancer Risk
Author Information
Author(s): Marsh H P, Haldar N A, Bunce M, Marshall S E, le Monier K, Winsey S L, Christodoulos K, Cranston D, Welsh K I, Harris A L
Primary Institution: Oxford Radcliffe Hospitals
Hypothesis
Do polymorphisms in TNF alter the risk of developing bladder cancer and subsequent tumor behavior?
Conclusion
The study found significant associations between TNF polymorphisms TNF+488A and TNF−859T with the risk of bladder cancer and the grade of tumors at presentation.
Supporting Evidence
- TNF+488A was found in 28.3% of bladder cancer patients compared to 13.1% of controls.
- TNF−859T was found in 26.3% of bladder cancer patients compared to 13.1% of controls.
- Significant associations were found between TNF polymorphisms and tumor grade at presentation.
Takeaway
This study looked at how certain genetic variations in a protein called TNF might make people more likely to get bladder cancer or affect how serious their cancer is.
Methodology
The study involved analyzing blood samples from bladder cancer patients and comparing them with control populations to identify TNF polymorphisms.
Potential Biases
Potential bias due to the reliance on a single center for patient recruitment and the limited demographic diversity of the control population.
Limitations
Complete clinical records were not available for all patients, which may affect the analysis of tumor stage and grade.
Participant Demographics
The study included 196 bladder cancer patients, with a median age of 68 years, comprising 151 males and 45 females.
Statistical Information
P-Value
0.0068 for TNF+488A, 0.017 for TNF−859T
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website